Catabasis Pharmaceuticals Stock Analysis
Technical stock analysis for Tue 11'th Dec 2018
Catabasis Pharmaceuticals gained 2.45% in the last trading day, rising from $0.60 to $0.61 , and has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. The price has risen in 7 of the last 10 days and is up by 6.02% over the past 2 weeks. Volume fell in the last day by -173 888 shares, and in total, 244 285 shares bought and sold for approximately $150 211.00. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.
Catabasis Pharmaceuticals lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -27.36% during the next 3 months and, with 90% probability hold a price between $0.36 and $0.48 at the end of this period.
A buy signal was issued from a pivot bottom point on Thursday December 06, 2018, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Catabasis Pharmaceuticals holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $0.62 and $0.64. A break-up above any of these levels will issue buy signals. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.
Relative Strength Index (RSI)
RSI14 is 53 and the stock is currently not being overbought or oversold
Support & Resistance
Catabasis Pharmaceuticals finds support from accumulated volume at $0.60.
This stock may move much during a day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.06 between high and low, or 10.53%. For the last week the stock has had a daily average volatility of 10.20%.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Very Low Low Medium High Very High
Catabasis Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
|CATB $0.61 $0.01(2.45%)|
CATB is up $0.01 today, but where's it headed in 2019?
|Zacks Investment Research is releasing its prediction for CATB based on the 1-3 month system that more than doubles the S&P 500.
Click here – the CATB analysis is free »